Winnipeg-based biotechnology firm Kane Biotech Inc. has showcased promising new clinical findings at a major international medical conference, reinforcing the potential of its advanced wound care solutions.
New Data Presented at Prestigious Forum
The company presented a series of case studies at the Innovations in Wound Healing (IWH) Annual Meeting, held in Key West, Florida from December 11 to 14, 2025. IWH is recognized as a leading scientific forum that connects top clinicians, researchers, and industry leaders to accelerate the adoption of breakthrough treatments that improve patient outcomes.
Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, stated that the presentations underscore the company's dedication to advancing wound care innovation. "By sharing our latest data at IWH, we continue to strengthen our role as a trusted partner in improving patient outcomes and supporting health systems with effective, science-driven solutions," Huizinga said.
Key Clinical Findings and Applications
The data presented covered several challenging wound types, demonstrating the versatility and efficacy of Kane's revyve Antimicrobial Wound Gel platform. The findings, drawn from real-world case studies, included several significant highlights:
Improved Healing in Chronic Wounds: Clinical outcomes demonstrated enhanced healing trajectories for patients suffering from persistent, non-healing wounds.
Versatility Across Care Standards: The technology showed efficacy across different application frequencies, dressing types, and wound varieties, including wounds with high levels of fluid discharge (exudative wounds).
Breakthrough in Radiation-Damaged Tissue: New findings focused on a Chronic Radiation-Induced Achilles Ulcer. The data indicated that Kane's gel technology can support healing in tissue compromised by radiation, where conventional therapies often fail.
Addressing Hidradenitis Suppurativa (HS): Case data illustrated revyve's potential to reduce the burden of infection and improve outcomes for patients with this painful and debilitating inflammatory skin condition.
Market Adoption and Regulatory Status
The presentation also included insights into how Kane's innovations are being integrated into clinical care pathways, delivering measurable value to healthcare systems. The company's flagship products, revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, have already received significant regulatory approvals.
Both products are cleared by the U.S. Food and Drug Administration (FDA) via the 510(k) pathway. Furthermore, the revyve Antimicrobial Wound Gel is approved by Health Canada, allowing for its use in the Canadian healthcare market.
Kane Biotech, which trades on the TSX Venture Exchange under the symbol TSX-V:KNE, focuses on developing novel treatments that disrupt harmful biofilms—a major contributor to antibiotic resistance in wounds. The revyve platform is designed to address both biofilms and wound bacteria simultaneously.
